source
- Roche reports updated eye drug data and FDA filing acceptance, targets July 2027 decisionRoche Genentech has presented new data from its eye disease trials, a year after a mixed Phase 3 readout, and noted that the FDA has accepted its filing for vamikibart with a decision slated for Ju…
- Tortugas Neuroscience's obuprazine shows significant improvement in phase 2b schizophrenia trial in ChinaTortugas Neuroscience, a biotech founded by former Sage Therapeutics staff with $106 million in funding, reported positive data from a phase 2b study of its schizophrenia candidate obuprazine, lice…